COPZ1 antibody targets the COPZ1 protein, a key component of the coatomer protein complex I (COPI), which mediates retrograde transport of vesicles within the Golgi apparatus and between the Golgi and endoplasmic reticulum (ER). COPI-coated vesicles are essential for maintaining Golgi structure, cargo sorting, and recycling of proteins to the ER. COPZ1. along with COPZ2. forms the ζ-subunit of the COPI complex, playing a critical role in binding to membrane surfaces and initiating vesicle budding. Research on COPZ1 has expanded to explore its involvement in cellular processes such as autophagy, lipid metabolism, and cell signaling. Dysregulation of COPZ1 is implicated in diseases, including cancer and neurodegenerative disorders. For instance, altered COPZ1 expression has been observed in certain cancers, potentially affecting tumor progression via disrupted vesicular trafficking. COPZ1 antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to study its expression, localization, and interactions in various models. These antibodies are typically raised in rabbits or mice using peptide antigens derived from conserved regions of the human COPZ1 protein. Commercial availability from suppliers like Abcam, Santa Cruz Biotechnology, and Cell Signaling Technology facilitates its use in both basic and translational research, aiding mechanistic studies of COPI-dependent trafficking and related pathologies.